SHOPPING CART
REGISTER
LOGIN
SEARCH

Diagnostic Testing & Technology Report

July 2009

Clarient Launches EGFR Mutation Testing to Aid in Therapy Selection for Non-Small Cell Lung Cancer

Anatomic pathology and molecular testing laboratory Clarient, Inc. (Aliso Viejo, Calif.), has launched a laboratory-developed test (LDT) that can help physicians select the proper therapy for patients with non-small cell lung cancer (NSCLC) by detecting mutations in the epidermal growth factor receptor (EGFR) gene.

Login | Subscribe

July 2009 - Table of Contents

DTTR July 2009 (full PDF issue)

Outreach Testing Programs Move to Integrate Diagnostic Services

Agendia Expands Stateside with New CLIA Laboratory

Medicare Part B Lab Spending Up 3.3% to $7.3 Billion in 2008

With New CLIA Lab, Perlegen Plans Fall Launch of Breast Cancer Test

Inside the Diagnostics Industry: At G-2�s Outreach Conference, an Emphasis on �Knowing Your Numbers� to Succeed in a Growing Market

Survey Finds Outreach Labs Averaging $26 in Revenue per Test

Special Focus: Pharmacogenomics: Clinical Data Sees Pharmacogenomic Test Revenues Climb 116 Percent

Quest Launches New HIV Tropism Test

Protein Marker Linked to Effectiveness of Pancreatic Cancer Drug

Clarient Launches EGFR Mutation Testing to Aid in Therapy Selection for Non-Small Cell Lung Cancer

Inverness Medical Innovations to Acquire Drug Testing Company

Genetically Elevated Lipoprotein Levels Linked to Heart Attack Risk

Myriad Genetics Clears Hurdles to Pharma Spin-Off

Legislation Would Revise �Date of Service� Policy for Complex Tests

CMS Projects Modest Growth in POLs Doing CLIA-Waived, PPM Tests

PLUS Diagnostics to Launch Hematology/Oncology Testing Services

Groups Can Help Fund Testing Services, Says OIG

IVD Stocks Gain 6%; Affymetrix Up 20%

G-2 Insider: Patients Choose Predictive Testing

Diagnostic Testing & Technology Report is part of...

Focus Areas	Product Group
G2 Reports Medical Lab Management	Newsletters